Leerink Partnrs Weighs in on Hologic, Inc.’s Q3 2025 Earnings (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) – Leerink Partnrs cut their Q3 2025 EPS estimates for shares of Hologic in a research report issued on Monday, October 7th. Leerink Partnrs analyst P. Souda now forecasts that the medical equipment provider will post earnings of $1.09 per share for the quarter, down from their previous estimate of $1.16. The consensus estimate for Hologic’s current full-year earnings is $4.09 per share.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, July 29th. The medical equipment provider reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.02 by $0.04. Hologic had a net margin of 17.59% and a return on equity of 19.53%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $1 billion. During the same period in the previous year, the company posted $0.93 EPS. Hologic’s revenue was up 2.7% compared to the same quarter last year.

A number of other analysts also recently issued reports on the stock. Leerink Partners dropped their target price on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a research report on Tuesday. Royal Bank of Canada reiterated a “sector perform” rating and issued a $82.00 target price on shares of Hologic in a research note on Friday, August 16th. Citigroup lowered Hologic from a “buy” rating to a “neutral” rating and lowered their price target for the company from $95.00 to $85.00 in a report on Tuesday, October 1st. StockNews.com lowered Hologic from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 27th. Finally, Stephens reaffirmed an “overweight” rating and set a $92.00 target price on shares of Hologic in a research note on Tuesday, July 30th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $87.50.

Hologic Price Performance

Hologic stock opened at $79.92 on Thursday. The firm has a market capitalization of $18.65 billion, a PE ratio of 40.78, a P/E/G ratio of 2.58 and a beta of 0.98. The company has a quick ratio of 3.32, a current ratio of 3.99 and a debt-to-equity ratio of 0.51. The firm’s 50-day simple moving average is $81.14 and its 200 day simple moving average is $77.55. Hologic has a 52 week low of $64.02 and a 52 week high of $84.67.

Insider Activity

In other news, CEO Stephen P. Macmillan sold 3,672 shares of the firm’s stock in a transaction dated Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total transaction of $294,237.36. Following the sale, the chief executive officer now owns 1,157,562 shares of the company’s stock, valued at $92,755,443.06. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Benjamin Jordan Cohn sold 5,093 shares of Hologic stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $81.99, for a total transaction of $417,575.07. Following the completion of the transaction, the insider now directly owns 10,476 shares in the company, valued at approximately $858,927.24. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Stephen P. Macmillan sold 3,672 shares of Hologic stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $80.13, for a total value of $294,237.36. Following the sale, the chief executive officer now directly owns 1,157,562 shares of the company’s stock, valued at approximately $92,755,443.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 18,280 shares of company stock valued at $1,469,973 over the last 90 days. 1.75% of the stock is owned by company insiders.

Institutional Trading of Hologic

Several hedge funds have recently added to or reduced their stakes in the company. Innealta Capital LLC bought a new position in shares of Hologic in the 2nd quarter valued at $25,000. iA Global Asset Management Inc. acquired a new position in Hologic during the 1st quarter worth approximately $37,000. Sunbelt Securities Inc. acquired a new position in Hologic during the 2nd quarter worth approximately $37,000. Cranbrook Wealth Management LLC purchased a new stake in shares of Hologic in the second quarter worth approximately $47,000. Finally, Mather Group LLC. purchased a new stake in shares of Hologic in the first quarter worth approximately $48,000. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.